Aperio Receives Second FDA Clearance for Diagnosis of Digital Breast Cancer Slides

I promise the Daily Scan won't turn into a mouthpiece for Aperio press releases, but this one is really important: Aperio Receives Second FDA Clearance for Diagnosis of Digital Breast Cancer Slides. 

The reason this is so important is that this is Aperio's second FDA clearance for a diagnosis made from a computer monitor.  We are the first (and so far, the only) company which has such clearances, which means we have demonstrated that what pathologists see on a computer monitor is equivalent to what you see with a microscope, for specific applications (in this case, diagnosis of PR-stained breast cancer slides).  The clearance covers Aperio's entire digital pathology system, comprising the ScanScope scanner, Spectrum digital slide management system, and ImageScope viewing software.

This clearance is important for Aperio, because it gives customers confidence that they can use digital pathology for diagnosis, but it is also important for the digital pathology industry as a whole.  Pathologists worldwide are adopting digital pathology and making their own professional judgement as to whether this technology allows them to see what they need to see in order to make diagnoses.  Obtaining FDA clearance on this capability shows that studies have been performed to validate their judgement, and will help accelerate the adoption of digital pathology technology.